You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
This week's news includes Ambry Genetics, DNAstack, Protea Biosciences Group, Exosome Diagnostics, BGI Europe, and Castle Biosciences.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.
The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.
Survey results reflect strong penetration of Castle Biosciences' uveal melanoma test among specialists as the company plans a future focus on more prevalent diseases.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.